SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs informs about company updates

29 Oct 2022 Evaluate
Laurus Labs has informed that US Food and Drug Administration (USFDA) today completed a Pre-Approval Inspection (PAI) at its manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. The inspection was conducted from 24th October 2022 to 28th October 2022. The company issued a Form 483 with one observation. The observation is procedural in nature. The Company will address the observation within stipulated timelines.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

1529.20 -12.55 (-0.81%)
06-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1913.05
Dr. Reddys Labs. 1368.75
Cipla 1471.25
Zydus Lifesciences 1148.05
Lupin 2492.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: